Close

Mr Elliot McClenaghan

Research Student - MPhil/PhD - Epidemiology & Population Health

United Kingdom

I am a doctoral candidate in Pharmacoepidemiology in the department of Medical Statistics and the Electronic Health Records group, where I investigate optimal causal inference and target trial emulation methodologies for treatment switching and deprescribing in cystic fibrosis. Previously I worked as a Research Fellow in the department of Infectious Disease Epidemiology and before that was a medical statistician at the UK Cystic Fibrosis Registry, where I designed and conducted post-authorisation drug safety studies and was lead statistician of a global registry collaboration on the impact of COVID-19 in people with cystic fibrosis. I studied Biomedical Sciences at Newcastle University and obtained an MPH in Public Health with a strong quantitative focus at Queen’s University Belfast.

Affiliations

Department of Medical Statistics
Faculty of Epidemiology and Population Health

Teaching

I have taught on various MSc modules and short courses at LSHTM including delivering lectures and co-organising on the Professional Certificate in Pharmacoepidemiology & Pharmacovigilance.

Research

My current doctoral research focuses on causal inference in pharmacoepidemiology and optimal statistical methods for target trial emulation using real-world data, applied to questions around treatment deprescribing and switching in cystic fibrosis. Previous work has focused on vaccine effectiveness, clinical data linkage and epidemiology of SARS-CoV-2 as part of the COVID-19 School Infection Survey collaboration. My previous research has also included drug safety, cystic fibrosis, global health and registry-based studies.

Research Area
Epidemiology
Applied statistics (medical)
Pharmacoepidemiology
Statistical methods
Disease and Health Conditions
Cystic fibrosis
COVID-19
Country
United Kingdom

Selected Publications

National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021SARS-CoV-2 antibody prevalence in school children.
Powell, AA; Ireland, G; Leeson, R; Lacey, A; Ford, B; Poh, J; Ijaz, S; Shute, J; Cherepanov, P; Tedder, R; BOTTOMLEY, C; Dawe, F; MANGTANI, P; Jones, P; NGUIPDOP-DJOMO, P; Ladhani, SN; COVID-19 Schools Infection Survey Group,;
2023
The Journal of infection
Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study.
Carr, SB; MCCLENAGHAN, E; Elbert, A; Faro, A; Cosgriff, R; Abdrakhmanov, O; Brownlee, K; Burgel, P-R; Byrnes, CA; Cheng, SY; Colombo, C; Corvol, H; Daneau, G; Goss, CH; Gulmans, V; Gutierrez, H; Harutyunyan, S; Helmick, M; Jung, A; Kashirskaya, N; McKone, E; Melo, J; Middleton, PG; Mondejar-Lopez, P; De Monestrol, I; ... CF Registry Global Collaboration,
2022
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.
Naehrlich, L; Orenti, A; Dunlevy, F; Kasmi, I; Harutyunyan, S; Pfleger, A; Keegan, S; Daneau, G; Petrova, G; Tješić-Drinković, D; Yiallouros, P; Bilkova, A; Olesen, HV; Burgel, P-R; Parulava, T; Diamantea, F; Párniczky, A; McKone, EF; Mei-Zahav, M; Salvatore, M; Colombo, C; Aleksejeva, E; Malakauskas, K; Schlesser, M; Fustik, S; ... European Cystic Fibrosis COVID project group,
2021
JOURNAL OF CYSTIC FIBROSIS
COVID-19 vaccine prioritisation for people with cystic fibrosis.
Carr, SB; Cosgriff, R; Harutyunyan, S; Middleton, PG; Ruseckaite, R; Ahern, S; Daneau, G; Filho, LV R F D S; Stephenson, AL; Cheng, SY; Melo, J; Corvol, H; Burgel, P-R; Nährlich, L; McKone, E; Colombo, C; Salvatore, M; Padoan, R; Abdrakhmanov, O; Gulmans, V; Byrnes, CA; Amelina, E; Kondratyeva, E; Zhekayte, E; Kashirskaya, N; ... Marshall, BC.
2021
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
P083 Clinical progression of SARS-CoV-2 infection in people with cystic fibrosis: a global observational study
MCCLENAGHAN, E; Cosgriff, R; Brownlee, K; Ahern, S; Burgel, P-R; Byrnes, CA; Colombo, C; Corvol, H; Cheng, SY; Daneau, G; Elbert, A; Faro, A; Goss, CH; Gulmans, V; Gutierrez, H; De Monestrol, I; Jung, A; Nährlich, L; Kashirskaya, N; Marshall, BC; McKone, E; Middleton, PG; Mondejar-Lopez, P; Pastor-Vivero, MD; Padoan, R; ... Carr, SB.
2021
Journal of Cystic Fibrosis
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.
MCCLENAGHAN, E; Cosgriff, R; Brownlee, K; Ahern, S; Burgel, P-R; Byrnes, CA; Colombo, C; Corvol, H; Cheng, SY; Daneau, G; Elbert, A; Faro, A; Goss, CH; Gulmans, V; Gutierrez, H; De Monestrol, I; Jung, A; Justus, LN; Kashirskaya, N; Marshall, BC; McKone, E; Middleton, PG; Mondejar-Lopez, P; Pastor-Vivero, MD; Padoan, R; ... Global Registry Harmonization Group,
2020
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
What Predicts Hospital Admissions in Community-Dwelling People With Parkinsonism?
Sebastian, R; Gray, WK; Foley, A; Trendall, L; Oh, D; Hand, A; Dodds, S; MCCLENAGHAN, E; Santos, VD; Oates, LL; Fisher, J; Walker, RW;
2019
Journal of geriatric psychiatry and neurology
Epidemiology of Nontuberculous Mycobacteria Infection in Children and Young People With Cystic Fibrosis: Analysis of UK Cystic Fibrosis Registry.
Gardner, AI; MCCLENAGHAN, E; Saint, G; McNamara, PS; Brodlie, M; Thomas, MF;
2018
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
See more information